• PainChek requests trading halt pending announcement on FDA regulatory clearance
• Trading halt effective from market open on 7 October 2025
• Trading halt to continue until announcement made, or before market open on 8 October 2025

PainChek Ltd (ASX: PCK) has requested a trading halt in its securities, effective from the commencement of trading on Tuesday, 7 October 2025. The company has requested the trading halt pending the release of an announcement regarding regulatory clearance from the U.S. Food and Drug Administration (FDA). PainChek states that the trading halt is necessary as otherwise trading in the company's securities would continue on an uninformed basis. The trading halt will remain in place until the earlier of: (1) PainChek making an announcement regarding the FDA regulatory clearance; (2) before the opening of trading on Wednesday, 8 October 2025; or (3) PainChek separately requesting that the trading halt be lifted. PainChek is a medical device company that has developed the world's first regulatory-cleared pain assessment tool, which is used to assess pain in people who cannot reliably self-report their pain, such as those living with dementia or other conditions. The company has attained regulatory clearance for its PainChek technology in several countries, and the FDA review in the United States is currently in progress.